F&S sciencePub Date : 2025-05-01DOI: 10.1016/j.xfss.2025.02.005
{"title":"Corrigendum to “From the Editor-in-Chief” (F S Sci 2025;6:1–3)","authors":"","doi":"10.1016/j.xfss.2025.02.005","DOIUrl":"10.1016/j.xfss.2025.02.005","url":null,"abstract":"","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 2","pages":"Page 261"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2025-05-01DOI: 10.1016/j.xfss.2024.12.003
Qinnan Zhang Ph.D., Maria Katz M.Sc., Benjamin Podgursky M.Sc., Nicholas Schuch B.S., Shenglai Li M.Sc., Noor Siddiqui M.Sc., Funda Suer Ph.D., Yuntao Xia Ph.D.
{"title":"Direct assessment of hereditary hemochromatosis in preimplantation genetic testing","authors":"Qinnan Zhang Ph.D., Maria Katz M.Sc., Benjamin Podgursky M.Sc., Nicholas Schuch B.S., Shenglai Li M.Sc., Noor Siddiqui M.Sc., Funda Suer Ph.D., Yuntao Xia Ph.D.","doi":"10.1016/j.xfss.2024.12.003","DOIUrl":"10.1016/j.xfss.2024.12.003","url":null,"abstract":"<div><h3>Objective</h3><div>Hereditary hemochromatosis (HH) is a common genetic disorder characterized by iron overload, which, if undiagnosed, can lead to severe organ damage. There are 4 types of HH. Type 1 HH, the most common form, is primarily caused by a common variant in Western Europe (p.Cys282Tyr, C282Y, or c.845 G>A). It is generally preventable during in vitro fertilization if proper genetic testing is performed before implantation. Here, we demonstrated a direct detection and cost-effective approach using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in preimplantation genetic testing (PGT) settings.</div></div><div><h3>Design</h3><div>We began by validating the assay with genomic deoxyribonucleic acid (DNA) from Coriell cell lines of known HFE C282Y genotypes, followed by testing patients’ genomic DNA samples. After establishing the assay on genomic DNA, we extended the assay to whole-genome amplified DNA from embryo biopsies.</div></div><div><h3>Subjects</h3><div>The subjects include cell line samples and human specimens and human embryo biopsies.</div></div><div><h3>Exposure</h3><div>Patients and embryos either carried or did not carry the HFE C282Y variant in their genome. No intervention was applied.</div></div><div><h3>Main Outcome Measures</h3><div>The readout included the genotype of samples at the HFE C282Y locus and accuracy of PCR-RFLP results.</div></div><div><h3>Results</h3><div>An accuracy of >99% was achieved across 80 cell line samples, 38 patient samples, and 81 embryo biopsies.</div></div><div><h3>Conclusion</h3><div>In this study, we demonstrated the feasibility of using the PCR-RFLP approach to PGT. Specifically, we validated the assay for the HFE C282Y variant, the primary cause of type 1 hemochromatosis. The assay was tested on genomic DNA and DNA resulting from whole-genome amplification, achieving >99% accuracy, sensitivity, precision, and specificity. These results also suggest the possibility for extending the PCR-RFLP approach to cover a broader range of conditions, such as spinal muscular atrophy, to benefit more patients currently ineligible for testing at PGT laboratories.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 2","pages":"Pages 195-201"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2025-02-01DOI: 10.1016/j.xfss.2024.12.001
Macarena B. Gonzalez Ph.D. , Nicole O. McPherson Ph.D. , Haley S. Connaughton B.Sc. , Yasmyn E. Winstanley Ph.D. , David T. Kennedy Ph.D. , Carl A. Campugan Ph.D. , Mark A. Febbraio Ph.D. , Michael Barry M.C.E. , Ryan D. Rose Ph.D. , Rebecca L. Robker Ph.D.
{"title":"Mitochondrial activator BGP-15 protects sperm quality against oxidative damage and improves embryo developmental competence","authors":"Macarena B. Gonzalez Ph.D. , Nicole O. McPherson Ph.D. , Haley S. Connaughton B.Sc. , Yasmyn E. Winstanley Ph.D. , David T. Kennedy Ph.D. , Carl A. Campugan Ph.D. , Mark A. Febbraio Ph.D. , Michael Barry M.C.E. , Ryan D. Rose Ph.D. , Rebecca L. Robker Ph.D.","doi":"10.1016/j.xfss.2024.12.001","DOIUrl":"10.1016/j.xfss.2024.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>To study the efficacy of mitochondrial activator BGP-15 to preserve sperm quality and competence against cellular damage.</div></div><div><h3>Design</h3><div>Spermatozoa from mice or humans were treated in vitro with BGP-15, and sperm quality markers were assessed. Spermatozoa from young (8–12 weeks old) or reproductively old (>14 months old) mice were treated with BGP-15 for 1 hour and assessed for sperm quality and preimplantation embryo development after in vitro fertilization. The safety of BGP-15 on offspring outcomes was assessed through embryo transfers. In parallel studies, spermatozoa from healthy (not infertile) men were incubated in hydrogen peroxide, to induce oxidative stress, plus increasing doses of BGP-15, and sperm quality was evaluated. Spermatozoa from patients undergoing assisted reproductive technology (ART) treatment were incubated in the optimized dose of BGP-15 for 30 minutes, and sperm quality was assessed.</div></div><div><h3>Subjects</h3><div>C57BL/6 mice (N = 4–15 per group) for sperm quality and embryo development. CBAF1 mice (n = 6 per group) produced embryos for transfer. Human spermatozoa were from men with no infertility diagnosis (n = 14-20) or men undergoing ART (n = 33) at a local fertility clinic.</div></div><div><h3>Exposure</h3><div>Mouse spermatozoa were treated with 10-μM BGP-15. Human spermatozoa were treated with BGP-15 at doses from 1 to 100 μM.</div></div><div><h3>Main Outcome Measures</h3><div>Sperm quality measures (mouse and human) included motility, mitochondrial membrane potential (JC-1 dye), deoxyribonucleic acid (DNA) fragmentation (“HALO” assay), and DNA oxidation (8-oxoguanine immunodetection). Mouse embryo and offspring measures included on-time development after in vitro fertilization, morphokinetic analysis, and blastocyst inner cell mass and trophectoderm cell number, and growth and development from birth to 21 days postnatally.</div></div><div><h3>Results</h3><div>BGP-15 increased sperm motility and mitochondrial membrane potential and decreased DNA oxidation in old mice. BGP-15 improved on-time development of 2-cell and blastocyst embryos and increased the inner cell mass blastomere number. Embryos from BGP-15-treated mouse spermatozoa produced normal offspring. In human spermatozoa subjected to in vitro oxidative stress, BGP-15 increased motility by 45% and prevented DNA fragmentation (by 45%) and oxidative damage (by 60%). In spermatozoa from men attending a fertility clinic, BGP-15 increased motility by 12% and reduced both DNA oxidation and fragmentation by >20%.</div></div><div><h3>Conclusion</h3><div>BGP-15 protects sperm against cellular damage and has the potential to improve ART outcomes.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 1","pages":"Pages 42-54"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2025-02-01DOI: 10.1016/j.xfss.2024.12.002
Sabrine Bensouda M.D. , Sarah C. Cromack M.D. , Allison S. Komorowski M.D. , Elena HogenEsch M.D. , Matthew J. Schipma Ph.D. , Xinkun Wang Ph.D. , Hailie Fowler M.S. , MaryEllen Pavone M.D., M.S.C.I. , Stefan J. Green Ph.D. , Lia A. Bernardi M.D., M.S.C.I. , Jennifer B. Bakkensen M.D., M.S.
{"title":"Uterine pathology and microbiome among patients with endometrial polyps and fibroids","authors":"Sabrine Bensouda M.D. , Sarah C. Cromack M.D. , Allison S. Komorowski M.D. , Elena HogenEsch M.D. , Matthew J. Schipma Ph.D. , Xinkun Wang Ph.D. , Hailie Fowler M.S. , MaryEllen Pavone M.D., M.S.C.I. , Stefan J. Green Ph.D. , Lia A. Bernardi M.D., M.S.C.I. , Jennifer B. Bakkensen M.D., M.S.","doi":"10.1016/j.xfss.2024.12.002","DOIUrl":"10.1016/j.xfss.2024.12.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the uterine microbiome among women with endometrial polyps and submucosal fibroids and to compare results between endometrial sampling techniques.</div></div><div><h3>Design</h3><div>Patients with polyps or fibroids were prospectively recruited before hysteroscopy, whereas patients undergoing retrieval for planned oocyte cryopreservation were recruited prospectively as controls. Three specimen types obtained for each patient were the distal 5 mm of an embryo catheter passed to the uterine fundus (C), endometrial tissue from an endometrial biopsy (T), and formalin-fixed paraffin-embedded (FFPE) endometrial tissue from the same endometrial biopsy. 16S ribosomal RNA gene amplicon sequencing was performed to analyze the structure of the endometrial microbiome.</div></div><div><h3>Subjects</h3><div>Thirty-seven participants including 28 women with polyps and/or fibroids and 9 controls.</div></div><div><h3>Exposure</h3><div>None.</div></div><div><h3>Main Outcome Measures</h3><div>Microbial taxonomic alpha and beta diversity; differential abundance of taxa.</div></div><div><h3>Results</h3><div>Across all sample types, participants with polyps had higher microbial alpha diversity than controls (4.3 vs. 5.1, <em>q</em> = 0.049), and microbial communities were significantly different (pairwise Permutational Multivariate Analysis of Variance (PERMANOVA) pseudo-F = 2.1, <em>q</em> = 0.003). These differences were observed when examining C specimens alone (5.4 vs. 6.4, <em>q</em> = 0.001; pairwise PERMANOVA pseudo-F = 2.5, <em>q</em> = 0.003), although they did not reach significance when examining either T or FFPE specimens alone. Participants with fibroids had similar alpha diversity yet significant differences in beta diversity compared with controls in analyses combining all specimens (pairwise PERMANOVA pseudo-F = 1.475, <em>q</em> = 0.030); however, these differences did not achieve significance when analyzing C, T, or FFPE specimens alone. When comparing C and T specimens vs. FFPE specimens overall, alpha diversity was significantly higher (<em>q</em> < 0.001 and <em>q</em> < 0.001, respectively) and there were significant differences in beta diversity (<em>q</em> < 0.003 and <em>q</em> < 0.003, respectively). Analyses of C specimens generated a larger number of significantly differentially abundant taxa compared with other sampling methods. Although not statistically significant, relative abundance of putative pathogens was higher in participants with polyps than controls regardless of sampling technique.</div></div><div><h3>Conclusions</h3><div>Results of this exploratory study suggest that significant microbial differences exist among patients with endometrial polyps vs. healthy controls. However, results varied by sampling technique, highlighting a need to identify optimal sampling methods before validating findings in larger prospective cohort studies.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 1","pages":"Pages 107-116"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2025-02-01DOI: 10.1016/j.xfss.2024.10.005
David Huang M.D. , Emily Flynn Ph.D , Ana Almonte-Loya B.S. , Brittany Davidson B.S. , Meagan Chan D.N.P. , Amber Casillas B.S. , Juan C. Irwin M.D., Ph.D. , Gabriela K. Fragiadakis Ph.D. , Hakan Cakmak M.D. , Alexis J. Combes Ph.D. , Marcelle I. Cedars M.D. , Marina Sirota Ph.D. , Linda C. Giudice M.D., Ph.D.
{"title":"A positive ReceptivaDx result for BCL6 does not correlate with abnormal ERA results or decreased expression of receptivity-associated markers: two sides of the endometrial receptivity coin in fertility evaluation and treatment","authors":"David Huang M.D. , Emily Flynn Ph.D , Ana Almonte-Loya B.S. , Brittany Davidson B.S. , Meagan Chan D.N.P. , Amber Casillas B.S. , Juan C. Irwin M.D., Ph.D. , Gabriela K. Fragiadakis Ph.D. , Hakan Cakmak M.D. , Alexis J. Combes Ph.D. , Marcelle I. Cedars M.D. , Marina Sirota Ph.D. , Linda C. Giudice M.D., Ph.D.","doi":"10.1016/j.xfss.2024.10.005","DOIUrl":"10.1016/j.xfss.2024.10.005","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate if a positive result on ReceptivaDx for evaluation of B-cell lymphoma 6 (BCL6), a proposed marker of progesterone resistance associated with impaired uterine receptivity, correlates with a suboptimal profile of receptivity-associated markers in the window of implantation using the endometrial receptivity array and single-nucleus transcriptomic analysis.</div></div><div><h3>Design</h3><div>Retrospective clinical cohort study; pilot study of single-nucleus RNA sequencing of prospectively collected window of implantation endometrium undergoing ReceptivaDx BCL6 evaluation.</div></div><div><h3>Subjects</h3><div>Patients with infertility who underwent endometrial biopsy for concurrent endometrial receptivity array analysis (ERA; Igenomix, Valencia, Spain) and BCL6 immunostaining (ReceptivaDx; Cicero Diagnostics, Inc., Huntington Beach, CA).</div></div><div><h3>Exposure</h3><div>Positive BCL6 result on ReceptivaDx (histologic score >1.4).</div></div><div><h3>Main Outcome Measures</h3><div>Prereceptive ERA result; relative expression levels of endometrial receptivity-associated epithelial genes by single-nucleus sequencing.</div></div><div><h3>Results</h3><div>One hundred and seventy-two patients with concurrent ERA and ReceptivaDx evaluation were included in the analysis: 40 were BCL6-positive and 132 were BCL6-negative. One patient (2.5%) in the BCL6-positive group had a prereceptive ERA result, compared with 29 patients (22.0%) in the BCL6-negative group (<em>P</em><.01). BCL6 positivity was associated with decreased odds of a prereceptive ERA result (odds ratio, 0.09; 95% confidence interval, 0.01–0.69; <em>P</em>=.02). Single-nucleus transcriptomic analysis of 5,718 epithelial cell nuclei from four individuals showed significant cell type-specific transcriptomic changes associated with a positive ReceptivaDx BCL6 result in both natural cycle (NC) and programmed cycle (PC) endometrium: there were 2,801 significantly differentially expressed genes comparing NC BCL6-positive with -negative, and 1,062 differentially expressed genes comparing PC BCL6-positive with -negative. Of the 34 receptivity-associated epithelial markers evaluated, 16 were significantly upregulated in NC BCL6-positive vs. -negative endometrium epithelial nuclei. In PC epithelial nuclei, 12 of the 34 receptivity-associated genes were significantly upregulated, whereas only one was significantly downregulated in BCL6-positive vs. -negative endometrium.</div></div><div><h3>Conclusions</h3><div>A positive ReceptivaDx BCL6 result does not correlate with a prereceptive ERA. Epithelial cells from BCL6-positive endometrium did not show significantly decreased expression in most of the receptivity markers evaluated. These findings demonstrate discordance between the interpretation of “endometrial receptivity” by ReceptivaDx and ERA, and highlight the need for further validation of endometrial evaluation methods in fertility treatment.</div></d","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 1","pages":"Pages 55-64"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2025-02-01DOI: 10.1016/j.xfss.2024.10.003
Ana Lobo de Almeida M.Sc. , Ana Gonçalves M.Sc. , Alberto Barros M.D., Ph.D. , Mário Sousa M.D., Ph.D. , Rosália Sá M.D., Ph.D.
{"title":"Bleomycin in vitro exposure decreases markers of human male gamete competence","authors":"Ana Lobo de Almeida M.Sc. , Ana Gonçalves M.Sc. , Alberto Barros M.D., Ph.D. , Mário Sousa M.D., Ph.D. , Rosália Sá M.D., Ph.D.","doi":"10.1016/j.xfss.2024.10.003","DOIUrl":"10.1016/j.xfss.2024.10.003","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the in vitro impact of bleomycin on human sperm deoxyribonucleic acid (DNA) integrity, functionality, and morphology, with the aim of elucidating the underlying mechanism and anticipating potential repercussions on patients’ reproductive function.</div></div><div><h3>Design</h3><div>Controlled laboratory-based in vitro investigation.</div></div><div><h3>Subjects</h3><div>Surplus human ejaculate donated for research by 45 reproductive-age participants exhibiting normozoospermic sperm parameters after clinical semen analysis. None of the participants had received a cancer diagnosis or undergone radiotherapy, chemotherapy, or both.</div></div><div><h3>Exposure</h3><div>After clinical semen analysis, sperm samples were centrifuged, diluted in sperm preparation medium, and exposed to bleomycin (100 μg/mL) for 2 hours at 37 °C in a humidified incubator with 5% CO<sub>2</sub>.</div></div><div><h3>Main Outcome Measures</h3><div>In vitro human sperm competence was evaluated by comparing raw sperm, sperm incubated with sperm preparation medium, and sperm exposed to bleomycin. Competence indicators included sperm motility, vitality, DNA and acrosome integrity, and mitochondrial membrane potential. Transmisson electron microscopy was employed to correlate the ultrastructural morphological findings with functional assays.</div></div><div><h3>Results</h3><div>Exposure to bleomycin for 2 hours in vitro significantly decreased sperm vitality, motility, and chromatin condensation compared with raw and control sperm. It also significantly increased sperm DNA fragmentation and the proportion of sperm with low mitochondrial membrane potential. Additionally, bleomycin significantly retarded the acrosomal response compared with control but did not affect the formation of intracellular and extracellular reactive oxygen species. Bleomycin-induced ultrastructural morphological changes supported the detected functional alterations.</div></div><div><h3>Conclusions</h3><div>Bleomycin negatively impacts male gamete competency in humans. Healthcare professionals should vigilantly monitor and further investigate the gonadotoxicity effects of bleomycin, in addition to its recognized lung toxicity. Meanwhile, it is recommended that patients with cancer undergoing bleomycin-containing chemotherapy regimens receive guidance on fertility preservation strategies.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"6 1","pages":"Pages 5-15"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F&S sciencePub Date : 2024-11-01DOI: 10.1016/j.xfss.2024.08.002
Alexander M. Quaas M.D., Ph.D. , Alan S. Penzias M.D. , Eli Y. Adashi M.D., M.S.
{"title":"Embryonic aneuploidy — the true “last barrier in assisted reproductive technology”?","authors":"Alexander M. Quaas M.D., Ph.D. , Alan S. Penzias M.D. , Eli Y. Adashi M.D., M.S.","doi":"10.1016/j.xfss.2024.08.002","DOIUrl":"10.1016/j.xfss.2024.08.002","url":null,"abstract":"<div><div>Human embryonic aneuploidy may represent one of the final frontiers in assisted reproductive technology, primarily secondary to oocyte aneuploidy. Mammalian oocytes possess unique characteristics predisposing them to much higher rates of aneuploidy than sperm or most somatic cells. Some of these characteristics are age-independent, whereas others result from reproductive aging and environmental toxicity. A detailed understanding of these properties may lead to novel diagnostic and therapeutic tools designed to detect and prevent oocyte and embryonic aneuploidy to overcome this ultimate barrier to success in assisted reproductive technology.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"5 4","pages":"Pages 303-305"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Engineered uterine primary myometrial cells with high-mobility group AT-hook 2 overexpression display a leiomyoma-like transcriptional and epigenomic phenotype","authors":"Priyanka Saini Ph.D. , Austin G. Holmes Ph.D. , Jian-Jun Wei M.D. , J. Brandon Parker Ph.D. , Debabrata Chakravarti Ph.D.","doi":"10.1016/j.xfss.2024.07.008","DOIUrl":"10.1016/j.xfss.2024.07.008","url":null,"abstract":"<div><h3>Objective</h3><div>To determine if engineered high-mobility group AT-hook 2 (HMGA2) overexpressing uterine primary myometrial cells recapitulate the transcriptional and epigenomic features of HMGA2-subtype leiomyomas.</div></div><div><h3>Design</h3><div>Isolated primary, “normal” myometrial cells from three patients were engineered to overexpress HMGA2 to determine how HMGA2 establishes transcriptomic and epigenomic features of HMGA2-overexpressing leiomyoma.</div></div><div><h3>Setting</h3><div>Academic research laboratory.</div></div><div><h3>Patient(s)</h3><div>Primary myometrial cells were isolated from normal myometrium obtained from three patients undergoing hysterectomy.</div></div><div><h3>Intervention(s)</h3><div>Not applicable.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Determined genome-wide transcriptomic and epigenomic features of engineered HMGA2-overexpressing uterine primary myometrial cells.</div></div><div><h3>Result(s)</h3><div>Engineered HMGA2-V5-overexpressing primary myometrial cells approximated the HMGA2 expression level observed in HMGA2-overexpression subtype leiomyoma. High-mobility group AT-hook 2-V5 expression resulted in differential expression of 1,612 genes (false discovery rate [FDR] < 0.05) that were found to be enriched in pathways associated with leiomyoma formation, including extracellular matrix organization. Comparative gene expression analysis between HMGA2-V5 engineered primary cells and HMGA2-overexpression subtype leiomyoma revealed significant overlap of differentially expressed genes. Mechanistically, HMGA2-V5 overexpression resulted in 41,323 regions with differential H3K27ac deposition (FDR < 0.05) and 205,605 regions of altered chromatin accessibility (FDR < 0.05). Transcription factor binding site analysis implicated the AP-1 family of transcription factors.</div></div><div><h3>Conclusion(s)</h3><div>High-mobility group AT-hook 2 overexpression induces leiomyoma-like transcriptomic and epigenomic modulations in myometrial cells.</div></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":"5 4","pages":"Pages 352-368"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}